Overview

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Patient's With Renal Impairment

Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is an open label, randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency in patients with different degrees of renal impairment.
Phase:
Phase 4
Details
Lead Sponsor:
Prove pharm